
    
      Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A
      using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the
      other side during their first clinic visit. This study is a pilot study designed to determine
      feasibility of these procedures.
    
  